Mounjaro feeling like it's wearing off on day 5? Here's what the evidence says

The misconception: your body is becoming immune to Mounjaro

The most common worry among people who notice hunger creeping back around day 5 is that their body has adapted and Mounjaro is no longer working. That conclusion is understandable but not supported by the evidence.

What is happening is simpler. Tirzepatide's half-life sits at around five days in most adults. After a weekly injection, the drug reaches peak plasma levels within roughly 24–48 hours, then the concentration gradually declines. By the time day 5 arrives, levels are lower than they were at the start of the week, and the dual GIP and GLP-1 receptor signals that reduce appetite and slow gastric emptying are therefore somewhat quieter. Appetite returns a little. Hunger cues that were suppressed become audible again.

This is a predictable consequence of the pharmacokinetics, not resistance or tolerance building. The NHS medicines page for tirzepatide explains that the medicine works by activating hormone pathways that regulate appetite and blood glucose, pathways that respond to the amount of drug present, which rises and falls on the weekly cycle. If you notice the difference more sharply on week 3 or 4, that is often because you are more attuned to the medicine's effects than you were in week 1, when you may not yet have known what to expect.

Worth knowing: most people find the variation less noticeable once they settle into a consistent injection routine and reach a stable maintenance dose.

What day 5 symptoms actually tell you about your current dose

The degree to which Mounjaro feels as though it is wearing off by day 5 can be a useful signal, but it needs interpreting carefully. A mild return of appetite (slightly more interest in food, hunger at mealtimes) is entirely within the expected range. A dramatic resurgence of cravings, significant nausea on injection day followed by pronounced hunger by the midweek mark, or a feeling that the medicine is providing no benefit at all: those patterns are worth flagging to a prescriber.

Mounjaro is licensed for weight management in adults as a once-weekly injection, with a structured titration schedule starting at 2.5mg. The prescriber who manages your treatment can review whether the wearing-off pattern you're describing suggests that a dose review is clinically appropriate, or whether lifestyle factors (sleep, stress, hydration, protein intake) are amplifying the end-of-week hunger signal.

One practical detail many people overlook: the pen you keep in the fridge door should be injected on the same day each week. Shifting the injection by even a day or two creates artificial peaks and troughs that make the pharmacological dip at day 5 feel sharper than it needs to be. Consistency doesn't solve the half-life, but it stops you making it worse. You can read more about how the medicine's activity changes across the week on our guide to when Mounjaro wears off.

If you're trying to understand whether what you're experiencing is the standard day-5 pattern or something that needs a clinical conversation, our Mounjaro day 5 overview covers the full picture across the first weeks of treatment.

When the wearing-off feeling is a signal to act

Not every day-5 dip warrants action beyond patience, but some presentations do need a prescriber's attention. The situations worth escalating are:

No meaningful appetite suppression at any point in the week. If hunger never reduced when you first started or after a dose change, the medicine may not be reaching therapeutic levels, or another factor may be in play. A prescriber reviewing your response can explore this.

The dip is getting worse over time. Some people notice that end-of-week hunger, manageable at 2.5mg, becomes more disruptive as they reach higher doses. Counterintuitively, higher doses extend suppression for more people, so this is often resolved through the titration process rather than despite it. Titration timing is a prescriber decision.

Side effects are intense at injection and negligible by day 5. Pronounced nausea on injection day followed by a sharp drop-off can sometimes point to absorption variation at the injection site. Rotating between the abdomen, thigh, and upper arm (as described in the Mounjaro SmPC on the eMC) is one factor a prescriber may discuss. If you want a closer look at why some people find that Mounjaro wears off after 5 days more noticeably than others, that pattern and the reasons behind it are explained in full on our dedicated page.

If you're considering how the cost of staying on treatment fits into longer-term planning, our Mounjaro pricing page sets out what private treatment typically involves. The detail on why Mounjaro produces the effects it does across a weekly cycle is covered thoroughly on our tirzepatide information page.

Mounjaro is a prescription-only medicine. A named GPhC-registered prescriber at a regulated pharmacy reviews each patient's treatment, decisions about dose, timing and response are always made at that level, not by the person taking the medicine alone. If you haven't yet started treatment and are exploring whether Mounjaro might be suitable for you, our Mounjaro overview explains the eligibility criteria and what the clinical assessment involves. The question our prescribers hear most often from patients at the day-5 mark is whether they should simply push through, and the honest answer is: it depends on the pattern, which is exactly what a prescriber review is for.

For a broader look at treatment options alongside Mounjaro, our weight-loss treatment page gives an honest comparison of what's currently available in the UK.